Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II TRIAL OF EDATREXATE IN SMALL-CELL LUNG-CANCER
Autore:
WIESENFELD A; JETT JR; SU JQ; BRAICH TA; KARDINAL CG; MAILLIARD JA; VEEDER MH; MORTON RF; MICHALAK JC;
Indirizzi:
CARE OF KNOWLTON L,N CENT CANC TREATMENT GRP,OPERAT OFF,200 1ST ST SWROCHESTER MN 55905 CEDAR RAPIDS ONCOL PROJECT COMMUNITY,CLIN ONCOL PROGRAM CEDAR RAPIDS IA 00000 MAYO CLIN & MAYO FDN,DEPT ONCOL ROCHESTER MN 55905 MAYO CLIN SCOTTSDALE,HEMATOL & ONCOL SECT SCOTTSDALE AZ 00000 OCHSNER COMMUNITY CLIN ONCOL PROGRAM NEW ORLEANS LA 00000 CREIGHTON UNIV,NEBRASKA ONCOL GRP OMAHA NE 00000 UNIV NEBRASKA,MED CTR OMAHA NE 00000 ILLINOIS ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM PEORIA IL 00000 IOWA ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM DES MOINES IA 00000 SIOUXLAND HEMATOL ONCOL ASSOCIATES SIOUX CITY IA 00000
Titolo Testata:
Cancer
fascicolo: 4, volume: 73, anno: 1994,
pagine: 1189 - 1193
SICI:
0008-543X(1994)73:4<1189:PTOEIS>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
PREVIOUSLY UNTREATED PATIENTS; MURINE TUMOR-MODELS; ONCOLOGY-GROUP; CHEMOTHERAPY; AGENT; 10-ETHYL-10-DEAZA-AMINOPTERIN; METHOTREXATE; CARCINOMA; CISPLATIN; PROGRESS;
Keywords:
EDATREXATE; 10-EDAM; SMALL CELL LUNG CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
A. Wiesenfeld et al., "PHASE-II TRIAL OF EDATREXATE IN SMALL-CELL LUNG-CANCER", Cancer, 73(4), 1994, pp. 1189-1193

Abstract

Background. Long-term survival with extensive stage small cell lung cancer is rare. There have been no major advances in the treatment of this stage of disease in the last 15-20 years. New agents with activityagainst this malignancy are needed. This study was designed to evaluate the efficacy of edatrexate against small cell lung cancer in a Phase II trial. Methods. This was a multicenter cooperative oncology grouptrial. Patients were either previously untreated or had failed only one prior chemotherapy regimen. All previously untreated patients had extensive stage disease. Patients in whom prior therapy had been unsuccessful had either limited or extensive stage disease. All cases had histologic documentation. Patients received edatrexate (80 mg/m(2)) intravenously over 20-30 minutes every 7 days. Previously untreated patients with disease progression at any time or stable disease after 6 weeks of treatment were crossed over to treatment with cisplatin and etoposide. The primary end points of the study were clinical response and toxicity to edatrexate. All patients were observed for survival. Results. Eleven previously untreated and 22 previously treated patients wereenrolled. A median of five doses of chemotherapy was given to each group. No major clinical response was observed in either group. The median survival time for the 11 previously untreated patients was 9.8 months versus 3.7 months for individuals who had received prior therapy. Myelosuppression and stomatitis were the primary toxicities, and both were infrequent. Conclusions. Edatrexate is inactive against small celllung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 03:23:46